Reference entry · Dual GLP-1/glucagon receptor agonist
Survodutide
Also known as: BI 456906 · GLP-1/glucagon dual agonist
- Class
- Dual GLP-1/glucagon receptor agonist
- Primary targets (literature)
- GLP-1 receptor, glucagon receptor
- Regulatory context
- Investigational — not FDA-approved. Catalog survodutide is RUO material without trial-grade GMP context.
Overview
Survodutide is a dual GLP-1/glucagon receptor agonist studied in metabolic and MASH (NAFLD/NASH) research trials. Human data are phase 2–stage, narrower than established incretin drugs.
Mechanism in research literature
Dual incretin plus glucagon agonism targets energy balance and hepatic lipid biology in sponsor-led metabolic and liver-disease research programs.
Common research focus areas
- MASH and obesity phase 2 trial literature
- Glucagon pathway monitoring in dual agonists
- Comparison with mazdutide and triple-agonist retatrutide
- Investigational peptide identity testing
Full literature roundup
Read the cited research summary
A dual GLP-1/glucagon receptor agonist studied in metabolic and MASH research trials. Phase 2 literature and RUO material considerations.
Survodutide research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.